AUTL Autolus Therapeutics plc ADRs

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$6.69  +0.11 (1.67%)
As of 09/17/2021 15:59:53 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  06/22/2018
Outstanding shares:  72,742,582
Average volume:  582,396
Market cap:   $480,101,041
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    05280R100
ISIN:        US05280R1005
Sedol:      BFMLGR4
Valuation   (See tab for details)
PE ratio:   -3.26
PB ratio:   1.69
PS ratio:   167.87
Return on equity:   -51.68%
Net income %:   -5,126.40%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy